Kfh - Downey
- Type
- Teaching hospital
- Where
- DOWNEY, CA
- Medicare CCN
- 050139
- Received
- $419,325 in 41 records, 2022 ($0 general, $419,325 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | Research payment | 41 | $419,325 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 1 | $135,375 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 2 | $117,910 | 2022 |
| Incyte Corporation | 22 | $100,709 | 2022 |
| Edwards Lifesciences Corporation | 6 | $57,102 | 2022 |
| TG Therapeutics, Inc. | 8 | $6,517 | 2022 |
| Endologix LLC | 1 | $1,561 | 2022 |
| Merck Sharp & Dohme LLC | 1 | $149 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 41 | $419,325 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-20 | E.R. Squibb & Sons, L.L.C. | $58,705 | Research payment | Cash or cash equivalent | NASH cohort algorithm and validation using a hospital based record system | 2022 | |
| 2022-12-14 | Incyte Corporation | $2,896 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-11-09 | Incyte Corporation | $556 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-10-21 | Edwards Lifesciences Corporation | $1,400 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2022 | |
| 2022-10-19 | Incyte Corporation | $556 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-09-28 | Incyte Corporation | $8,543 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-09-27 | Edwards Lifesciences Corporation | $4,440 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-09-08 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $684 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $615 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $615 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-09-08 | Incyte Corporation | $615 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2022 | |
| 2022-08-24 | Edwards Lifesciences Corporation | $13,500 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2022 | |
| 2022-08-10 | Incyte Corporation | $2,842 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-08-03 | Incyte Corporation | $3,832 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-06-22 | Incyte Corporation | $5,812 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-06-17 | JAZZ PHARMACEUTICALS INC. | $135,375 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-06-02 | Edwards Lifesciences Corporation | $13,500 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2022 | |
| 2022-06-02 | Incyte Corporation | $2,500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-05-18 | Incyte Corporation | $23,995 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-05-11 | Incyte Corporation | $3,817 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-04-22 | Endologix LLC | $1,561 | Research payment | Cash or cash equivalent | AFX2 Bifurcated Endograft System Device, Cardiology/Vascular Diseases | LEOPARD | 2022 |
| 2022-04-21 | Edwards Lifesciences Corporation | $10,667 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-04-13 | Incyte Corporation | $14,009 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-03-02 | Incyte Corporation | $1,303 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-02-16 | Incyte Corporation | $13,871 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-02-16 | Incyte Corporation | $5,647 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2022 | |
| 2022-02-10 | TG Therapeutics, Inc. | $2,158 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2022 |
| 2022-02-10 | TG Therapeutics, Inc. | $2,158 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2022 |
| 2022-02-09 | E.R. Squibb & Sons, L.L.C. | $59,205 | Research payment | Cash or cash equivalent | NASH cohort algorithm and validation using a hospital based record system | 2022 | |
| 2022-01-26 | Edwards Lifesciences Corporation | $13,595 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-01-13 | TG Therapeutics, Inc. | $600 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previou | 2022 |
| 2022-01-13 | TG Therapeutics, Inc. | $600 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previou | 2022 |
| 2022-01-13 | TG Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2022 |
| 2022-01-13 | TG Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2022 |
| 2022-01-13 | TG Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib | 2022 |
| 2022-01-13 | TG Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Downey, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Downey, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 110,939 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 114,355 | 10,014,009 | 39,538,223 |
| Median age B01002 | 37.7 | 38.2 | 37.9 |
| Under 18 B01001 | 21.3% | 20.6% | 22.0% |
| 65 and over B01001 | 14.2% | 15.2% | 15.7% |
| Households B11001 | 34,876 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 32.2% | 33.4% | 27.0% |
| Median household income B19013 | $90,699 | $90,112 | $99,122 |
| Median family income B19113 | $97,325 | $101,573 | $113,346 |
| Per capita income B19301 | $38,523 | $45,792 | $49,513 |
| Poverty rate B17001 | 9.0% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.8% | 7.3% | 6.6% |
| Civilian labor force B23025 | 59,357 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 31.0 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 26.1% | 36.0% | 37.1% |
| Housing units B25001 | 35,919 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 51.1% | 45.9% | 55.9% |
| Renters B25003 | 48.9% | 54.1% | 44.1% |
| Median home value B25077 | $796,600 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,937 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 11.8% | 24.7% | 33.8% |
| Black B03002 | 3.4% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 75.3% | 48.4% | 40.2% |
| Asian B03002 | 7.3% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Downey, CA.
Comments